Brief: Silo Pharma Set To Acquire Exclusive Licensing For Alzheimer’s Disease Therapeutic From Columbia University
10/04/2024 13:15
April 10 (Reuters) - Silo Pharma Inc SILO.O :
* SILO PHARMA SET TO ACQUIRE EXCLUSIVE LICENSING FOR
PROMISING
ALZHEIMER’S DISEASE THERAPEUTIC
* SILO PHARMA INC - COMPANY EXPECTS TO FINALIZE AND ENTER
INTO
EXCLUSIVE LICENSE AGREEMENT IN FIRST HALF OF 2024
* SILO PHARMA INC - BELIEVES THAT SPC-14 SHOULD BE ELIGIBLE
FOR
DEVELOPMENT UNDER FDA'S 505(B)(2) REGULATORY PATHWAY
* SILO PHARMA INC - UNDER TERMS, SILO WILL BE GRANTED AN
EXCLUSIVE
LICENSE TO FURTHER DEVELOP, MANUFACTURE, AND COMMERCIALIZE
SPC-14 WORLDWIDE
Source text for Eikon: ID:nGNXB1hj5
Further company coverage: SILO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement